Autoantibodies to neurotransmitter receptors and ion channels: From neuromuscular to neuropsychiatric disorders

Frontiers in Genetics

Volumn 4, Issue SEP, 2013, Pages

  Martinez Martinez, Pilar ^a   Molenaar, Peter C ^a   Losen, Mario ^a   Stevens, Jo ^a   De Baets, Marc H ^a   Szoke, Andrei ^b,c,d   Honnorat, Jerome ^e,f   Tamouza, Ryad ^g   Leboyer, Marion ^b,c,d   Van Os, Jim ^a   Rutten, Bart P F ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSERM U955   (France)

^d FONDATION FONDAMENTAL   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f UNIVERSITÉ LYON 1   (France)

^g SAINT LOUIS HOSPITAL   (France)

Author keywords

Acetylcholine receptor; AMPA receptor; Caspr2; GABA receptor; Glycine receptor; Lgi1; NMDA receptor; Potassium channel

Indexed keywords

EID: 84886023820     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2013.00181     Document Type: Review

References (82)

1. Borda, T., Gomez, R., Berria, M. I., and Sterin-Borda, L. (2004). Antibodies against astrocyte M1 and M2 muscarinic cholinoceptor from schizophrenic patients' sera. Glia 45, 144-154. doi:10.1002/glia.10312.
2. Borda, T., Perez Rivera, R., Joensen, L., Gomez, R. M., and Sterin-Borda, L. (2002). Antibodies against cerebral M1 cholinergic muscarinic receptor from schizophrenic patients:molecular interaction. J. Immunol. 168, 3667-3674.
3. Cannon, S. C. (2010). Voltage-sensor mutations in channelopathies of skeletal muscle. J. Physiol. 588, 1887-1895. doi:10.1113/jphysiol.2010.186874.
4. Chandley, M. J., Miller, M. N., Kwasigroch, C. N., Wilson, T. D., and Miller, B. E. (2009). Increased antibodies for the alpha7 subunit of the nicotinic receptor in schizophrenia. Schizophr. Res. 109, 98-101. doi:10.1016/j.schres.2009.01.023.
5. Cole, R. N., Reddel, S. W., Gervasio, O. L., and Phillips, W. D. (2008). Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann. Neurol. 63, 782-789. doi:10.1002/ana.21371.
6. Cooper, G. S., Bynum, M. L., and Somers, E. C. (2009). Recent insights in the epidemiology of autoimmune diseases:improved prevalence estimates and understanding of clustering of diseases. J. Autoimmun. 33, 197-207. doi:10.1016/j.jaut.2009.09.008.
7. Corti, C., Xuereb, J. H., Crepaldi, L., Corsi, M., Michielin, F., and Ferraguti, F. (2011). Altered levels of glutamatergic receptors and Na+/K+ ATPase-alpha1 in the prefrontal cortex of subjects with schizophrenia. Schizophr. Res. 128, 7-14. doi:10.1016/j.schres.2011.01.021.
8. Crespi, B. J., and Thiselton, D. L. (2011). Comparative immunogenetics of autism and schizophrenia. Genes Brain Behav. 10, 689-701. doi:10.1111/j.1601-183X.2011.00710.x.
9. Creten, C., Van Der Zwaan, S., Blankespoor, R. J., Maatkamp, A., Nicolai, J., Van Os, J., et al. (2011). Late onset autism and anti-NMDA-receptor encephalitis. Lancet 378, 98. doi:10.1016/S0140-6736(11)60548-5.
10. Cutler, R. W., Watters, G. V., and Hammerstad, J. P. (1970). The origin and turnover rates of cerebrospinal fluid albumin and gamma-globulin in man. J. Neurol. Sci. 10, 259-268. doi:10.1016/0022-510X(70)90154-1.
11. Cvetkovic-Lopes, V., Bayer, L., Dorsaz, S., Maret, S., Pradervand, S., Dauvilliers, Y., et al. (2010). Elevated tribbles homolog 2-specific antibody levels in narcolepsy patients. J. Clin. Invest. 120, 713-719. doi:10.1172/JCI41366.
12. Dalmau, J., Lancaster, E., Martinez-Hernandez, E., Rosenfeld, M. R., and Balice-Gordon, R. (2011). Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 10, 63-74. doi:10.1016/S1474-4422(10)70253-2.
13. Dalton, P., Deacon, R., Blamire, A., Pike, M., Mckinlay, I., Stein, J., et al. (2003). Maternal neuronal antibodies associated with autism and a language disorder. Ann. Neurol. 53, 533-537. doi:10.1002/ana.10557.
14. DeGiorgio, L. A., Konstantinov, K. N., Lee, S. C., Hardin, J. A., Volpe, B. T., and Diamond, B. (2001). A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 7, 1189-1193. doi:10.1038/nm1101-1189.
15. Diamond, B., Huerta, P. T., Mina-Osorio, P., Kowal, C., and Volpe, B. T. (2009). Losing your nerves? Maybe it's the antibodies. Nat. Rev. Immunol. 9, 449-456. doi:10.1038/nri2529.
16. Engel, A. G., Ohno, K., Milone, M., Wang, H. L., Nakano, S., Bouzat, C., et al. (1996). New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Hum. Mol. Genet. 5, 1217-1227. doi:10.1093/hmg/5.9.1217.
17. Engel, A. G., Ohno, K., and Sine, S. M. (1999). Congenital myasthenic syndromes:recent advances. Arch. Neurol. 56, 163-167. doi:10.1001/archneur.56.2.163.
18. Errichiello, L., Perruolo, G., Pascarella, A., Formisano, P., Minetti, C., Striano, S., et al. (2009). Autoantibodies to glutamic acid decarboxylase (GAD) in focal and generalized epilepsy:a study on 233 patients. J. Neuroimmunol. 211, 120-123. doi:10.1016/j.jneuroim.2009.04.010.
19. Faber, C. G., Molenaar, P. C., Vles, J. S., Bonifati, D. M., Verschuuren, J. J., Van Doorn, P. A., et al. (2009). AChR deficiency due to epsilon-subunit mutations:two common mutations in the Netherlands. J. Neurol. 256, 1719-1723. doi:10.1007/s00415-009-5190-7.
20. Fabian, R. H., and Hulsebosch, C. E. (1989). Time course of penetration of xenogeneic IgG into the central nervous system of the neonatal rat:an immunohistochemical and radionuclide tracer study. J. Neuroimmunol. 24, 183-189. doi:10.1016/0165-5728(89)90116-1.
21. Fontaine, B., Fournier, E., Sternberg, D., Vicart, S., and Tabti, N. (2007). Hypokalemic periodic paralysis:a model for a clinical and research approach to a rare disorder. Neurotherapeutics 4, 225-232. doi:10.1016/j.nurt.2007.01.002.
22. Frye, R. E., Sequeira, J. M., Quadros, E. V., James, S. J., and Rossignol, D. A. (2013). Cerebral folate receptor autoantibodies in autism spectrum disorder. Mol. Psychiatry 18, 369-381. doi:10.1038/mp.2011.175.
23. Fukaya, M., Hayashi, Y., and Watanabe, M. (2005). NR2 to NR3B subunit switchover of NMDA receptors in early postnatal motoneurons. Eur. J. Neurosci. 21, 1432-1436. doi:10.1111/j.1460-9568.2005.03957.x.
24. Fukunaga, H., Engel, A. G., Lang, B., Newsom-Davis, J., and Vincent, A. (1983). Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc. Natl. Acad. Sci. U.S.A. 80, 7636-7640. doi:10.1073/pnas.80.24.7636.
25. Ganguli, R., Brar, J. S., Chengappa, K. N., Yang, Z. W., Nimgaonkar, V. L., and Rabin, B. S. (1993). Autoimmunity in schizophrenia:a review of recent findings. Ann. Med. 25, 489-496. doi:10.3109/07853899309147317.
26. Gomez, A. M., Van Den Broeck, J., Vrolix, K., Janssen, S. P., Lemmens, M. A., Van Der Esch, E., et al. (2010). Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Autoimmunity 43, 353-370. doi:10.3109/08916930903555943.
27. Graef, S., Schonknecht, P., Sabri, O., and Hegerl, U. (2011). Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control:an overview of preclinical and clinical findings. Psychopharmacology (Berl.) 215, 205-229. doi:10.1007/s00213-010-2153-8.
28. Graus, F., Saiz, A., and Dalmau, J. (2010). Antibodies and neuronal autoimmune disorders of the CNS. J. Neurol. 257, 509-517. doi:10.1007/s00415-009-5431-9.
29. Honnorat, J., and Antoine, J. C. (2007). Paraneoplastic neurological syndromes. Orphanet J. Rare Dis. 2, 22. doi:10.1186/1750-1172-2-22.
30. Hutchinson, M., Waters, P., McHugh, J., Gorman, G., O'Riordan, S., Connolly, S., et al. (2008). Progressive encephalomyelitis, rigidity, and myoclonus:a novel glycine receptor antibody. Neurology 71, 1291-1292. doi:10.1212/01.wnl.0000327606.50322.f0.
31. Irani, S. R., Alexander, S., Waters, P., Kleopa, K. A., Pettingill, P., Zuliani, L., et al. (2010). Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 133, 2734-2748. doi:10.1093/brain/awq213.
32. Irani, S. R., Michell, A. W., Lang, B., Pettingill, P., Waters, P., Johnson, M. R., et al. (2011). Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann. Neurol. 69, 892-900. doi:10.1002/ana.22307.
33. Jones, C. A., Watson, D. J., and Fone, K. C. (2011). Animal models of schizophrenia. Br. J. Pharmacol. 164, 1162-1194. doi:10.1111/j.1476-5381.2011.01386.x.
34. Jurkat-Rott, K., Holzherr, B., Fauler, M., and Lehmann-Horn, F. (2010a). Sodium channelopathies of skeletal muscle result from gain or loss of function. Pflugers Arch. 460, 239-248. doi:10.1007/s00424-010-0814-4.
35. Jurkat-Rott, K., Lerche, H., Weber, Y., and Lehmann-Horn, F. (2010b). Hereditary channelopathies in neurology. Adv. Exp. Med. Biol. 686, 305-334. doi:10.1007/978-90-481-9485-8_18.
36. Jurkat-Rott, K., and Lehmann-Horn, F. (2004). Electrophysiology and molecular pharmacology of muscle channelopathies. Rev. Neurol. (Paris) 160, S43-S48. doi:10.1016/S0035-3787(04)71005-X.
37. Katzav, A., Solodeev, I., Brodsky, O., Chapman, J., Pick, C. G., Blank, M., et al. (2007). Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum. 56, 938-948. doi:10.1002/art.22419.
38. Klooster, R., Plomp, J. J., Huijbers, M. G., Niks, E. H., Straasheijm, K. R., Detmers, F. J., et al. (2012). Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 135, 1081-1101. doi:10.1093/brain/aws025.
39. Kullmann, D. M., and Waxman, S. G. (2010). Neurological channelopathies:new insights into disease mechanisms and ion channel function. J. Physiol. 588, 1823-1827. doi:10.1113/jphysiol.2010.190652.
40. Lai, M., Huijbers, M. G., Lancaster, E., Graus, F., Bataller, L., Balice-Gordon, R., et al. (2010). Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels:a case series. Lancet Neurol. 9, 776-785. doi:10.1016/S1474-4422(10)70137-X.
41. Lang, B., and Newsom-Davis, J. (1995). Immunopathology of the Lambert-Eaton myasthenic syndrome. Springer Semin. Immunopathol. 17, 3-15. doi:10.1007/BF00194096.
42. Lang, B., and Vincent, A. (2009). Autoimmune disorders of the neuromuscular junction. Curr. Opin. Pharmacol. 9, 336-340. doi:10.1016/j.coph.2009.04.005.
43. Lapteva, L., Nowak, M., Yarboro, C. H., Takada, K., Roebuck-Spencer, T., Weickert, T., et al. (2006). Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum. 54, 2505-2514. doi:10.1002/art.22031.
44. Lehmann-Horn, F., and Jurkat-Rott, K. (1999). Voltage-gated ion channels and hereditary disease. Physiol. Rev. 79, 1317-1372.
45. Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., Pittock, S. J., Lucchinetti, C. F., Fujihara, K., et al. (2004). A serum autoantibody marker of neuromyelitis optica:distinction from multiple sclerosis. Lancet 364, 2106-2112. doi:10.1016/S0140-6736(04)17551-X.
46. Lorenzon, N. M., and Beam, K. G. (2000). Calcium channelopathies. Kidney Int. 57, 794-802. doi:10.1046/j.1523-1755.2000.00917.x.
47. Martin, L. A., Ashwood, P., Braunschweig, D., Cabanlit, M., Van De Water, J., and Amaral, D. G. (2008). Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism. Brain Behav. Immun. 22, 806-816. doi:10.1016/j.bbi.2007.12.007.
48. Masdeu, J. C., Gonzalez-Pinto, A., Matute, C., Ruiz De Azua, S., Palomino, A., De Leon, J., et al. (2012). Serum IgG antibodies against the NR1 subunit of the NMDA receptor not detected in schizophrenia. Am. J. Psychiatry 169, 1120-1121. doi:10.1176/appi.ajp.2012.12050646.
49. Matthews, E., and Hanna, M. G. (2010). Muscle channelopathies:does the predicted channel gating pore offer new treatment insights for hypokalaemic periodic paralysis? J. Physiol. 588, 1879-1886. doi:10.1113/jphysiol.2009.186627.
50. Monyer, H., Burnashev, N., Laurie, D. J., Sakmann, B., and Seeburg, P. H. (1994). Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12, 529-540. doi:10.1016/0896-6273(94)90210-0.
51. Newsom-Davis, J. (2004). Neuromyotonia. Rev. Neurol. (Paris) 160, S85-S89. doi:10.1016/S0035-3787(04)71010-3.
52. Nicholson, T. R., Ferdinando, S., Krishnaiah, R. B., Anhoury, S., Lennox, B. R., Mataix-Cols, D., et al. (2012). Prevalence of anti-basal ganglia antibodies in adult obsessive-compulsive disorder:cross-sectional study. Br. J. Psychiatry 200, 381-386. doi:10.1192/bjp.bp.111.092007.
53. Omdal, R., Brokstad, K., Waterloo, K., Koldingsnes, W., Jonsson, R., and Mellgren, S. I. (2005). Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur. J. Neurol. 12, 392-398. doi:10.1111/j.1468-1331.2004.00976.x.
54. Oosterhuis, H. J., Newsom-Davis, J., Wokke, J. H., Molenaar, P. C., Weerden, T. V., Oen, B. S., et al. (1987). The slow channel syndrome. Two new cases. Brain 110, 1061-1079. doi:10.1093/brain/110.4.1061.
55. Panza, F., Frisardi, V., Imbimbo, B. P., D'onofrio, G., Pietrarossa, G., Seripa, D., et al. (2010). Bapineuzumab:anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy 2, 767-782. doi:10.2217/imt.10.80.
56. Phillips, L. H. II. (2003). The epidemiology of myasthenia gravis. Ann. N.Y. Acad. Sci. 998, 407-412. doi:10.1196/annals.1254.053.
57. Poduslo, J. F., Curran, G. L., and Berg, C. T. (1994). Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc. Natl. Acad. Sci. U.S.A. 91, 5705-5709. doi:10.1073/pnas.91.12.5705.
58. Pusch, M. (2002). Myotonia caused by mutations in the muscle chloride channel gene CLCN1. Hum. Mutat. 19, 423-434. doi:10.1002/humu.10063.
59. Ramaekers, V. T., Blau, N., Sequeira, J. M., Nassogne, M. C., and Quadros, E. V. (2007). Folate receptor autoimmunity and cerebral folate deficiency in low-functioning autism with neurological deficits. Neuropediatrics 38, 276-281. doi:10.1055/s-2008-1065354.
60. Ramaekers, V. T., Rothenberg, S. P., Sequeira, J. M., Opladen, T., Blau, N., Quadros, E. V., et al. (2005). Autoantibodies to folate receptors in the cerebral folate deficiency syndrome. N. Engl. J. Med. 352, 1985-1991. doi:10.1056/NEJMoa043160.
61. Riemersma, S., Vincent, A., Beeson, D., Newland, C., Hawke, S., Vernet-Der Garabedian, B., et al. (1996). Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. J. Clin. Invest. 98, 2358-2363. doi:10.1172/JCI119048.
62. Ryan, D. P., Da Silva, M. R., Soong, T. W., Fontaine, B., Donaldson, M. R., Kung, A. W., et al. (2010). Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell 140, 88-98. doi:10.1016/j.cell.2009.12.024.
63. Ryan, D. P., and Ptacek, L. J. (2010). Episodic neurological channelopathies. Neuron 68, 282-292. doi:10.1016/j.neuron.2010.10.008.
64. Shillito, P., Molenaar, P. C., Vincent, A., Leys, K., Zheng, W., Van Den Berg, R. J., et al. (1995). Acquired neuromyotonia:evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann. Neurol. 38, 714-722. doi:10.1002/ana.410380505.
65. Smoller, J. W., Craddock, N., Kendler, K., Lee, P. H., Neale, B. M., Ripke, S., et al. (2013). Identification of risk loci with shared effects on five major psychiatric disorders:a genome-wide analysis. Lancet 381, 1371-1379. doi:10.1016/S0140-6736(12)62129-1.
66. Solimena, M., Folli, F., Denis-Donini, S., Comi, G. C., Pozza, G., De Camilli, P., et al. (1988). Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N. Engl. J. Med. 318, 1012-1020. doi:10.1056/NEJM198804213181602.
67. Steiner, J., Walter, M., Glanz, W., Sarnyai, Z., Bernstein, H. G., Vielhaber, S., et al. (2013). Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia:specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry 70, 271-278. doi:10.1001/2013.jamapsychiatry.86.
68. Stephan, K. E., Baldeweg, T., and Friston, K. J. (2006). Synaptic plasticity and dysconnection in schizophrenia. Biol. Psychiatry 59, 929-939. doi:10.1016/j.biopsych.2005.10.005.
69. 2+ channelopathies. Biochem. Biophys. Res. Commun. 322, 1341-1346. doi:10.1016/j.bbrc.2004.08.039.
70. ter Beek, W. P., Martinez-Martinez, P., Losen, M., De Baets, M. H., Wintzen, A. R., Verschuuren, J. J., et al. (2009). The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates. Am. J. Pathol. 175, 1536-1544. doi:10.2353/ajpath.2009.090040.
71. van Os, J., Kenis, G., and Rutten, B. P. (2010). The environment and schizophrenia. Nature 468, 203-212. doi:10.1038/nature09563.
72. Vincent, A. (2010). Autoimmune channelopathies:well-established and emerging immunotherapy-responsive diseases of the peripheral and central nervous systems. J. Clin. Immunol. 30(Suppl. 1), S97-S102. doi:10.1007/s10875-010-9401-x.
73. Vincent, A., Bien, C. G., Irani, S. R., and Waters, P. (2011). Autoantibodies associated with diseases of the CNS:new developments and future challenges. Lancet Neurol. 10, 759-772. doi:10.1016/S1474-4422(11)70096-5.
74. Vincent, A., Deacon, R., Dalton, P., Salmond, C., Blamire, A. M., Pendlebury, S., et al. (2002). Maternal antibody-mediated dyslexia? Evidence for a pathogenic serum factor in a mother of two dyslexic children shown by transfer to mice using behavioural studies and magnetic resonance spectroscopy. J. Neuroimmunol. 130, 243-247. doi:10.1016/S0165-5728(02)00226-6.
75. Vincent, A., and Leite, M. I. (2005). Neuromuscular junction autoimmune disease:muscle specific kinase antibodies and treatments for myasthenia gravis. Curr. Opin. Neurol. 18, 519-525. doi:10.1097/01.wco.0000180660.57801.3f.
76. Vincent, A., McConville, J., Farrugia, M. E., Bowen, J., Plested, P., Tang, T., et al. (2003). Antibodies in myasthenia gravis and related disorders. Ann. N.Y. Acad. Sci. 998, 324-335. doi:10.1196/annals.1254.036.
77. Vukadinovic, Z., and Rosenzweig, I. (2012). Abnormalities in thalamic neurophysiology in schizophrenia:could psychosis be a result of potassium channel dysfunction? Neurosci. Biobehav. Rev. 36, 960-968. doi:10.1016/j.neubiorev.2011.11.005.
78. Warren, R. P., Cole, P., Odell, J. D., Pingree, C. B., Warren, W. L., White, E., et al. (1990). Detection of maternal antibodies in infantile autism. J. Am. Acad. Child Adolesc. Psychiatry 29, 873-877. doi:10.1097/00004583-199011000-00005.
79. Wiescholleck, V., and Manahan-Vaughan, D. (2013). Long-lasting changes in hippocampal synaptic plasticity and cognition in an animal model of NMDA receptor dysfunction in psychosis. Neuropharmacology 74, 48-58. doi:10.1016/j.neuropharm.2013.01.001.
80. Wintzen, A. R., Plomp, J. J., Molenaar, P. C., Van Dijk, J. G., Van Kempen, G. T., Vos, R. M., et al. (1998). Acquired slow-channel syndrome:a form of myasthenia gravis with prolonged open time of the acetylcholine receptor channel. Ann. Neurol. 44, 657-664. doi:10.1002/ana.410440412.
81. Yoshio, T., Onda, K., Nara, H., and Minota, S. (2006). Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 54, 675-678. doi:10.1002/art.21547.
82. Zandi, M. S., Irani, S. R., Lang, B., Waters, P., Jones, P. B., McKenna, P., et al. (2011). Disease-relevant autoantibodies in first episode schizophrenia. J. Neurol. 258, 686-688. doi:10.1007/s00415-010-5788-9.